Summary
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis
Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.
Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?
Spyre has a broad clinical pipeline and cash runway, but elevated valuation makes upcoming readouts critical to its investment case.
SYRE Rallies 44.9% in 3 Months. Can Clinical Catalysts Sustain It?
Spyre's 2026 clinical catalysts and positive ulcerative colitis data fuel momentum, but its lofty valuation raises the stakes for upcoming readouts.
Spyre Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 99 | $2,120.78 | $9,734.67 | $7,613.89 | 359.01% |
| NA Nizar Araji National Bank Of Canada /FI/ | 124 | $11,179.84 | $13,008.84 | $1,829 | 16.36% |
| BG Bart Gancher Intech Investment Management LLC | 17,628 | $406,507.47 | $1.85M | $1.44M | 354.94% |
| JM John Malone Amundi | 2,793 | $251,816.88 | $294,186.69 | $42,369.81 | 16.83% |
 Anthony Scaramucci SkyBridge Capital II LLC | 137,588 | $4.68M | $14.26M | $9.58M | 204.59% |
Spyre Therapeutics, Inc. (SYRE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Spyre Therapeutics, Inc. ever had a stock split?
Spyre Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Cameron Turtle CEO | NASDAQ (NGS) Exchange | 00773J202 CUSIP |
| US Country | 125 Employees | - Last Dividend | 8 Sep 2023 Last Split | - IPO Date |
Overview
Spyre Therapeutics, Inc., initially known as Aeglea BioTherapeutics, Inc. until its name change in November 2023, is a preclinical stage biotech entity engaged in discovering and developing therapeutic solutions for individuals suffering from Inflammatory Bowel Disease (IBD). With its incorporation dating back to 2013 and headquarter located in Waltham, Massachusetts, the company stands out for its dedication to innovating in the IBD therapeutic landscape. Spyre Therapeutics endeavors to address the pressing needs of patients battling ulcerative colitis and Crohn's disease by leveraging advanced biotechnological approaches to develop monoclonal antibodies designed for precise, targeted treatment strategies.
Products and Services
The company's product pipeline showcases a series of pioneering monoclonal antibodies and their combinations, primarily in preclinical development stages, outlined as follows:
- SPY001: A groundbreaking human monoclonal immunoglobulin G1 (IgG1) antibody that exhibits selectivity for the α4β7 integrin. SPY001's design focuses on mitigating the effects of IBD by specifically targeting a crucial element in the inflammation process, showcasing its potential as a treatment option for ulcerative colitis and Crohn’s disease.
- SPY002: This candidate is a human monoclonal antibody (mAb) conceptualized to bind with tumor necrosis factor-like ligand 1A (TL1A), which plays a significant role in the inflammatory pathway, suggesting its utility in handling various inflammatory conditions beyond IBD.
- SPY120: Reflecting a combination therapy approach, SPY120 merges the anti-α4β7 effects of SPY001 with the anti-TL1A properties of SPY002. By targeting two distinct pathways pivotal in inflammation and immune response, this combination holds promise in offering a more comprehensive treatment modality for IBD patients.
- SPY003: Targets IL-23, another key inflammatory cytokine, through a specific anti-IL-23 monoclonal antibody (mAb). Given the critical role of IL-23 in chronic inflammation and autoimmune diseases, SPY003 delineates an innovative therapeutic avenue for IBD management.
- SPY004: Represents a novel mechanism of action (MOA) monoclonal antibody (mAb), the details of which underline Spyre Therapeutics' commitment to broadening the scope of biologic therapeutics in IBD, by potentially unlocking new pathways and targets for intervention.
- SPY130: A combination therapy that integrates the anti-inflammatory mechanisms of anti-α4β7 and anti-IL-23 mAbs, aiming at a synergistic approach to counteract the intricate network of signals involved in IBD pathology.
- SPY230: Brings together the functions of anti-TL1A and anti-IL-23 monoclonal antibodies, targeting a dual pathway strategy to comprehensively address the multifaceted mechanisms of inflammation present in IBD and similar disorders.
